Envestnet Asset Management Inc. Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Envestnet Asset Management Inc. grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 11.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,614 shares of the biotechnology company’s stock after purchasing an additional 4,847 shares during the period. Envestnet Asset Management Inc.’s holdings in Sarepta Therapeutics were worth $5,546,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank purchased a new position in Sarepta Therapeutics during the 4th quarter valued at about $126,315,000. Brandywine Global Investment Management LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at approximately $22,613,000. Swedbank AB purchased a new stake in Sarepta Therapeutics during the 4th quarter worth approximately $16,706,000. Vanguard Group Inc. lifted its holdings in Sarepta Therapeutics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after buying an additional 117,904 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Sarepta Therapeutics by 16,717.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 84,926 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $55.23 on Tuesday. The business has a 50 day simple moving average of $81.12 and a 200-day simple moving average of $107.25. Sarepta Therapeutics, Inc. has a 12 month low of $48.01 and a 12 month high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The stock has a market capitalization of $5.36 billion, a PE ratio of 44.18 and a beta of 0.93.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on SRPT shares. Scotiabank decreased their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a report on Thursday, March 20th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. Needham & Company LLC dropped their price objective on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a research report on Thursday, April 3rd. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an “overweight” rating for the company in a research report on Monday. Finally, HC Wainwright reissued a “neutral” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, April 16th. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.70.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.